1904-24-1

Usage

Uses

Used in Organic Synthesis:
5-AMINO-3-ETHYL-1H-PYRAZOLE is used as a key intermediate for the synthesis of various organic compounds. Its presence in the molecular structure allows for further functionalization and the creation of a wide range of products.
Used in Pharmaceutical Industry:
5-AMINO-3-ETHYL-1H-PYRAZOLE is used as a building block in the development of new pharmaceuticals. Its unique chemical properties make it a valuable component in the design and synthesis of novel drugs with potential therapeutic applications.
Used in Agrochemicals:
5-AMINO-3-ETHYL-1H-PYRAZOLE is used as a raw material in the production of agrochemicals, such as pesticides and herbicides. Its incorporation into these products can enhance their effectiveness and selectivity, leading to improved agricultural outcomes.
Used in Dye Industry:
5-AMINO-3-ETHYL-1H-PYRAZOLE is used as an intermediate in the synthesis of various dyes and pigments. Its chemical properties contribute to the development of dyes with specific color characteristics and improved performance in various applications.

InChI:InChI=1/C5H9N3/c1-2-4-3-5(6)8-7-4/h3H,2H2,1H3,(H3,6,7,8)

Upstream product

• 33279-01-5 3-oxo-pentanenitrile 
• 554-12-1 propanoic acid methyl ester 
• 75-05-8 acetonitrile 

Downstream Products

• 1440804-91-0 C₂₀H₃₀N₄O₂ 
• 927679-37-6 3-((2-chloro-6-(5-ethyl-1H-pyrazol-3-ylamino)pyrimidin-4-yl)methyl)benzonitrile 
• 1269515-89-0 N-(2-ethylpyrazolo[1,5-a]pyrimidin-6-yl)-2,6-difluoro-3-(propylsulfonamido)benzamide 
• 1356003-22-9 C₈H₁₀N₄ 
• 948573-57-7 N-(5-ethyl-1H-pyrazol-3-yl)-2-(4-benzyloxy-2-methoxyphenyl)acetamide 
• 927679-40-1 6-benzyl-2-chloro-N-(5-ethyl-1H-pyrazol-3-yl)pyrimidin-4-amine 
• 1241916-22-2 (4-(5-ethyl-1H-pyrazol-3-ylamino)quinazolin-2-yl)(4-fluorophenyl)methanone 
• 1035201-76-3 2-(5-ethyl-1H-pyrazol-3-yl)-1H-isoindole-1,3(2H)-dione 
• 203176-85-6 2,6-Diethyl-1-[2'-(1-trityl-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1H-pyrazolo[1,5-b][1,2,4]triazole 

Relevant academic research and scientific papers

Discovery of 2,4-diaminopyrimidine derivatives targeting p21-activated kinase 4: Biological evaluation and docking studies

In this study, novel 2,4-diaminopyrimidine derivatives targeting p21-activated kinase 4 (PAK4) were discovered and evaluated for their biological activity against PAK4. Among the derivatives studied, promising compounds A2, B6, and B8 displayed the highest inhibitory activities against PAK4 (IC50 = 18.4, 5.9, and 20.4 nM, respectively). From the cellular assay, compound B6 exhibited the highest potency with an IC50 value of 2.533 μM against A549 cells. Some compounds were selected for computational ADME (absorption, distribution, metabolism, and elimination) properties and molecular docking studies against PAK4. The detailed structure–activity relationship based on the biochemical activities and molecular docking studies were explored. According to the docking studies, compound B6 had the lowest docking score (docking energy: ?7.593 kcal/mol). The molecular docking simulation indicated the binding mode between compound B6 and PAK4. All these results suggest compound B6 as a useful candidate for the development of a PAK4 inhibitor.

Synthesis of pyrazolopyrimidinones using a “one-pot” approach under microwave irradiation

A simple one-pot method for the microwave-assisted synthesis of substituted pyrazolo[1,5-a]pyrimidinones, a core scaffold in many bioactive and pharmaceutically relevant compounds, has been established. A variety of substituents was tolerated at the 2 and 5 positions, including functionalized aryls, heterocycles, and alkyl groups.

BENZENE SULFONAMIDES AS CCR9 INHIBITORS

The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).

Pyrazolotriazines as inhibitors of nucleases

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3 and R4 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.

PYRROLOTRIAZINE KINASE INHIBITORS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit tyrosine kinase activity of such as Jak2 and CK2, thereby making them useful as antiproliferative agents for the treat

PYRROLOTRIAZINE KINASE INHIBITORS

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of such as TrkA, TrkB, TrkC, Jak2, Jak3 and CK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

QUINOLINE DERIVATIVES

The invention concerns quinoline derivatives of Formula (I): or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

QUINOLINE DERIVATIVES FOR TREATING CANCER

The invention concerns quinoline derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.